Ropes & Gray Represents Genesis Therapeutics in a Genentech Partnership on AI Drug Discovery and Development
Ropes & Gray advised Genesis Therapeutics, a Stanford University launched company, in a digital health partnership with Roche unit Genentech. The collaboration will focus on using Genesis’ graph machine learning technology to develop an artificial intelligence-driven drug discovery platform to identify new drug candidates that target and treat several different severe diseases.
Under terms of the agreement, Genesis will receive an upfront payment and is eligible to receive pre-clinical, clinical and regulatory milestone payments, as well as future royalties on Genentech’s sales of approved drugs resulting from the collaboration.
The Ropes & Gray team included life sciences licensing partners Marc Rubenstein and Amanda Austin (both of Boston) and Megan Baca (Silicon Valley), and IP transactions and licensing associate Georgina Jones Suzuki (Silicon Valley).